drugset / Trial / NCT06437951
to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
to evaluate the safety/tolerability and pharmacokinetics, and pharmacodynamics after intravenous DWP14012 injection in healthy participants
Timeline
- Start
- 2024-07
- Primary completion
- 2025-01
- Completion
- 2025-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABEPRAZAN | Small molecule | 20 mg | Intravenous |
| Subject | ABEPRAZAN | Small molecule | 40 mg | Intravenous |
| Subject | ABEPRAZAN | Small molecule | 80 mg | Intravenous |